Retatrutide: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. Retatrutide is an investigational compound, not approved for any use by the FDA or Health Canada, and is discussed here strictly as a research compound.

Last updated: July 2026

---

If you’ve been anywhere near the peptide research community in the last two years, you’ve heard about retatrutide — usually described in the same breath as “the strongest one” or “the one that beats bariatric surgery numbers.” Both of those things are, remarkably, close to true. What’s less well understood is what that third receptor is actually doing, and what it means that this compound still isn’t approved anywhere.

Retatrutide: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. Retatrutide is an investigational compound, not approved for any use by the FDA or Health Canada, and is discussed here strictly as a research compound.

Last updated: July 2026

---

If you’ve been anywhere near the peptide research community in the last two years, you’ve heard about retatrutide — usually described in the same breath as “the strongest one” or “the one that beats bariatric surgery numbers.” Both of those things are, remarkably, close to true. What’s less well understood is what that third receptor is actually doing, and what it means that this compound still isn’t approved anywhere.

Quick Facts

Class	Triple GIP/GLP-1/Glucagon receptor agonist
Receptor targets	GLP-1, GIP, and glucagon
Administration	Once weekly, subcutaneous
Half-life	~6 days
Typical effective range (community-reported)	1mg–3mg weekly
Studied range	Up to 12mg weekly
Evidence tier	High for efficacy (multiple completed Phase 3 trials); no long-term real-world data yet — not approved
Regulatory status	Not yet approved anywhere; NDA filing expected late 2026
Phase 3 program began reporting	2025–2026

The Story So Far

Retatrutide’s path has been unusually fast by pharmaceutical standards, and unusually visible — the peptide research community has been watching each trial readout in close to real time, which is part of why it’s generated more online discussion than any compound in this guide series before it’s even been approved for anything.

The compound (known in trial documentation as LY3437943) moved through Phase 2 testing with results published in the New England Journal of Medicine in 2023 — 24.2% mean weight loss at 48 weeks at the highest dose tested, the largest number anyone had seen from a GLP-1-class compound at that point, alongside a striking secondary finding: up to 80% relative reduction in liver fat by MRI. That result alone was enough to make retatrutide the most anticipated compound in the category heading into Phase 3.

The Phase 3 program, called TRIUMPH, has been reporting results in stages rather than all at once. TRIUMPH-4, focused on adults with obesity and knee osteoarthritis, reported in December 2025: 28.7% average weight loss at 68 weeks on the 12mg dose, alongside meaningful reductions in knee pain — a genuinely novel angle, since it directly connects weight loss to a specific, measurable quality-of-life outcome rather than the scale alone. TRANSCEND-T2D-1, studying retatrutide specifically in people with type 2 diabetes, reported in March 2026, with 16.8% weight loss at 40 weeks on the 12mg dose — lower than the general-obesity numbers, consistent with the pattern seen across this entire drug class, where weight loss tends to be somewhat more modest in diabetic populations.

Then, on May 21, 2026, Eli Lilly announced topline results from TRIUMPH-1, the pivotal general-obesity trial and the one most of this guide is built around. In 2,339 participants over 80 weeks, the 12mg dose produced 28.3% average weight loss (70.3 lbs), with 45.3% of participants losing 30% or more of their body weight — a threshold historically associated with bariatric surgery outcomes. The 4mg dose, reached with only a single titration step, still produced 19.0% average weight loss. A study extension in participants with a baseline BMI of 35 or higher found weight loss continuing out to 104 weeks, reaching an average of 30.3%.

As of this writing, retatrutide is not approved anywhere. Eli Lilly has indicated an NDA filing is expected before the end of 2026, with two more Phase 3 trials — TRIUMPH-2 (studying retatrutide in type 2 diabetes) and TRIUMPH-3 (studying it in people with established cardiovascular disease) — still to report. Realistic approval timelines put market availability somewhere in 2027 to 2028, assuming no unexpected safety findings emerge from the remaining trials.

What It Actually Does

Semaglutide activates one hormone receptor. Tirzepatide activates two. Retatrutide activates three — adding glucagon receptor activation on top of the same GLP-1 and GIP pathways its predecessors use. That third pathway changes the equation in a specific way: where the other two compounds primarily work by making you eat less, retatrutide’s glucagon component also increases how much energy your body burns and how much fat it oxidizes directly — even independent of how much you’re eating. It’s not just appetite suppression; it’s appetite suppression plus a genuine increase in energy expenditure, which is the mechanistic explanation for why its trial results outpace even tirzepatide’s by a meaningful margin.

What the Research Shows

The evidence here is unusual in shape: unusually strong on efficacy, unusually thin on everything else, simply because of how recently and how quickly this compound has moved through trials.

The Phase 2 trial (2023) established the ceiling everyone has been watching since — 24.2% mean weight loss at 48 weeks, plus the striking 80% relative liver fat reduction finding that first suggested this compound might matter well beyond weight management alone.

TRIUMPH-4 (December 2025) extended the evidence into a specific comorbidity — knee osteoarthritis — finding 28.7% weight loss at 68 weeks alongside real reductions in joint pain, the first time this drug class has shown a direct musculoskeletal benefit this clearly tied to weight loss itself.

TRANSCEND-T2D-1 (March 2026) provided the first look at retatrutide specifically in a diabetic population, with more modest but still substantial 16.8% weight loss at 40 weeks — useful context, since most of the headline numbers in circulation come from non-diabetic populations.

TRIUMPH-1 (May 2026), the pivotal trial, is the number most public discussion of retatrutide is built around: 28.3% mean weight loss at 80 weeks on the 12mg dose, extending to 30.3% by 104 weeks in a higher-BMI subgroup. This is Phase 3 data in over 2,300 participants, not a projection or an early-phase signal.

What’s missing, and worth being honest about: there is no cardiovascular outcomes data yet (TRIUMPH-3 is still pending), no long-term real-world post-marketing experience of any kind, and no approval anywhere in the world. Every number above comes from controlled trial populations, not the kind of years-long, millions-of-patients real-world experience that backs semaglutide’s safety profile specifically.

How It Compares

Retatrutide sits at the far end of this category on raw efficacy, and at the far end of the other direction on evidence maturity.

	Semaglutide	Tirzepatide	Retatrutide
Receptor targets	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Approx. weight reduction (trial data)	~15% at 68 weeks (STEP 1)	~20.9% at 72 weeks (SURMOUNT-1, 15mg)	~28.3% at 80 weeks (TRIUMPH-1, 12mg)
Years of real-world data	~9 years (approved 2017)	~4 years (approved 2022)	None — not yet approved
Cardiovascular outcome data	Extensive — SUSTAIN-6, SELECT, SOUL	Substantial — SURPASS-CVOT, SUMMIT	None — TRIUMPH-3 still pending
Kidney outcome data	Yes — FLOW trial	Emerging	None yet
Regulatory status	Fully approved (multiple formulations)	Fully approved	Not yet submitted; NDA filing expected late 2026
Best evidence maturity for	Longest track record; broadest approved label	Strongest efficacy with a real, maturing safety record	Maximum documented efficacy; effectively zero real-world experience

The honest way to frame this: retatrutide currently produces the largest, most consistently documented weight loss of any compound in this category, across multiple large Phase 3 trials, in multiple populations. That’s genuinely impressive and not hype. But it is, unavoidably, the newest and least real-world-tested compound of the three by a wide margin — every other compound in this table has years of approved use behind the trial data; retatrutide has none. A researcher prioritizing maximum documented effect size has good reason to be interested in retatrutide specifically. A researcher prioritizing the deepest possible safety confidence has good reason to still prefer semaglutide or tirzepatide, at least until retatrutide accumulates real-world experience of its own.

Who Shouldn’t Use This

Retatrutide doesn’t yet have an approved drug label, so there’s no official FDA or Health Canada contraindications list to point to the way there is for semaglutide and tirzepatide. What follows is based on the exclusion criteria used consistently across its clinical trial program, which is the closest available proxy:

• Personal or family history of medullary thyroid carcinoma (MTC). Consistent with every other compound in this receptor class, and treated as a hard stop in trial eligibility criteria.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• History of pancreatitis.
• Severe gastrointestinal disease, including gastroparesis.
• Pregnancy or breastfeeding.

Given the additional glucagon receptor mechanism specifically, a few situations call for extra caution beyond what applies to semaglutide and tirzepatide:

• Any condition affecting blood glucose regulation beyond type 2 diabetes, since glucagon receptor activity has more direct effects on glucose metabolism than the GLP-1/GIP pathways alone — this is genuinely less studied territory than the other two compounds.
• Concurrent use of insulin or sulfonylureas, for the same hypoglycemia-risk reasons that apply across this drug class.
• Planned surgery within 30 days and history of gallbladder disease, for the same reasons that apply to semaglutide and tirzepatide.

Because there is no approved label and no long-term post-marketing safety record, the honest position here is more caution than confidence. If any of the above applies to you — or if you’re simply risk-averse about using a compound with this little real-world history — that’s a reasonable, defensible position, not an overreaction.

Common Myths, Addressed

“It’s basically tirzepatide, just stronger.” The glucagon receptor component is a functionally different addition, not just an increment — it’s the reason retatrutide increases energy expenditure directly, which tirzepatide’s mechanism doesn’t do. The size of the difference in trial results reflects a genuinely different mechanism, not just a bigger dose of the same idea.

“Since it produces the most weight loss, it’s the best choice for everyone.” The headline numbers come from the top of the studied dose range (12mg) in controlled trial populations. Community-reported experience — consistent with the pattern seen for semaglutide and tirzepatide — suggests most researchers land at considerably lower doses, and the tradeoff for the largest possible effect size is using a compound with no real-world safety track record at all.

“It’s not approved, so it must not be safe.” Lack of approval reflects where retatrutide is in the regulatory process, not a finding against it — the Phase 3 data so far has been consistently positive across multiple large trials. But it’s fair to say the absence of evidence for long-term safety is a real limitation, not a non-issue — it’s simply too early for that evidence to exist yet, for any compound.

What Researchers Are Actually Experiencing

Because retatrutide isn’t approved and has the shortest history of any compound in this comparison, community-reported experience here is thinner and newer than what exists for semaglutide or tirzepatide — worth keeping in mind as you read this section.

What is consistently reported mirrors the broader GLP-1/GIP pattern: titration-phase nausea and GI discomfort are the most common early experience, and they’re reported as most pronounced during the earliest dose steps, easing with patience and slower titration.

A theme specific to retatrutide’s community discussion is a stronger emphasis on staying at conservative doses. Given the size of the effect even at low doses in trial data — 19.0% weight loss at just 4mg in TRIUMPH-1 — a recurring point in community discussion is that there’s little reason to chase the 12mg ceiling when meaningful results are documented well below it.

Because it’s the newest compound in this category and isn’t available through any regulated channel, sourcing quality is discussed even more heavily in retatrutide-specific community spaces than it is for semaglutide or tirzepatide, both of which are at least available as regulated pharmaceuticals for those who prefer that route.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, individual experience varies, and the body of community experience here is simply younger than for the other two compounds in this category.

The Practical Basics

Titration Schedule

Phase	Weekly Dose	Duration
Titration	1mg	4 weeks
Titration	2mg	4 weeks
Titration	4mg	4 weeks
Active	6mg	4+ weeks
Active	8mg	4+ weeks
Advanced	10–12mg	Ongoing research phase

TRIUMPH-1’s own trial dosing used a somewhat different, faster ladder — 4mg was reached with only a single escalation step in that trial. The schedule above reflects a more conservative, commonly used community approach rather than the exact trial protocol. As with semaglutide and tirzepatide, most researchers don’t reach the top of this ladder and don’t need to — real-world community data consistently shows the majority land at 3mg or below and stay there, a range that’s well below the trial’s dosing ceiling but still substantial given the compound’s triple mechanism.

Hold your current dose if side effects haven’t resolved or it’s been less than 4 weeks since your last increase. Consider lowering if side effects are meaningfully affecting your ability to eat or function normally. Only raise after a full 4 weeks at your current dose, once side effects have settled. Never increase dose to “catch up” after a missed week — resume at your last well-tolerated dose.

Worked Dose Math

At 10mg/mL (a 20mg vial reconstituted with 2mL BAC water — the most common community combination):

• 1mg → 0.1mL → 10 units
• 2mg → 0.2mL → 20 units
• 4mg → 0.4mL → 40 units
• 8mg → 0.8mL → 80 units

At 5mg/mL (a 10mg vial reconstituted with 2mL BAC water):

• 1mg → 0.2mL → 20 units
• 2mg → 0.4mL → 40 units
• 4mg → 0.8mL → 80 units

The underlying rule: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe. At 10mg/mL, the mental math stays clean across the entire dose range this guide covers — 1mg is always 10 units, 2mg is always 20 units — which is part of why it’s the most popular vial-and-volume combination in community use.

Vial Planning

A 20mg vial at 10mg/mL gives you 20mg total. At a steady 2mg/week, that’s 10 weeks per vial. At 8mg/week, closer to 2.5 weeks. Match your vial size to your expected protocol length before ordering. For the full reconstitution walkthrough and math for every vial size and concentration, see our dedicated reconstitution guide.

Reconstitution and Storage — The Short Version

Retatrutide follows the standard approach: reconstitute with BAC water, refrigerate at 2–8°C, and use within 28 days. Nothing about retatrutide specifically deviates from this. For the complete process and troubleshooting, see our dedicated reconstitution and storage guide.

Sourcing

Because retatrutide is not available through any regulated pharmaceutical channel, sourcing quality matters more here than for any other compound in this category — see our full guide on reading a Certificate of Analysis and vetting a vendor for the complete picture.

Administration

Once weekly subcutaneous injection, same day each week, standard site rotation (abdomen, thigh, or upper arm). No fasting requirement.

Best Practices

• Hydrate consistently, especially through titration.
• Prioritize protein intake at every meal. With trial-documented weight loss this large even at moderate doses, protecting lean mass through adequate protein matters at least as much here as with tirzepatide.
• Consider electrolytes if GI side effects include vomiting or diarrhea, or if food intake drops significantly.
• Eat smaller, more frequent meals if nausea or early satiety is significant.
• Go lighter on fat around injection day, since high-fat meals close to injection time are commonly reported to worsen GI side effects, consistent with what’s reported across this drug class.
• Track your protocol from day one — dose, injection date, weight or measurements, and side effects, at minimum.

Common Mistakes to Avoid

• Chasing the 12mg ceiling because it’s the headline trial number, rather than recognizing that meaningful results are well documented at 3mg or below.
• Rushing the titration schedule — the most common cause of severe GI side effects and early discontinuation across this entire drug class.
• Not recording the reconstitution volume, turning every dose calculation into a guess.
• Underestimating the sourcing risk that comes with a compound that has no regulated supply chain at all, unlike semaglutide or tirzepatide.
• Under-eating protein during a deficit this large.

What Happens If You Stop

This is genuinely the least-answered question for retatrutide specifically — there is no published discontinuation or dose-reduction trial for this compound yet, unlike semaglutide (STEP 1 extension) or tirzepatide (SURMOUNT-4, SURMOUNT-MAINTAIN). What we can say is based on the consistent pattern across every other compound in this drug class: weight regain after stopping is well-documented for semaglutide and tirzepatide, and there’s no mechanistic reason to expect retatrutide would behave differently, given it works through overlapping and even broader pathways than either of them.

Until compound-specific discontinuation data exists, the reasonable, conservative assumption is that retatrutide’s effects are similarly maintained by continued use rather than “cured” by a period of treatment — the same pattern seen everywhere else in this category. Go in with a plan for the end of a protocol, not just the beginning, and don’t assume this compound will be an exception to a pattern that’s been consistent across every related compound studied so far.

What to Expect, Week by Week

• Weeks 1–4 (1mg–2mg): Often minimal noticeable weight change; this phase is about tolerability. Mild GI symptoms are most common here.
• Weeks 5–12 (4mg): Trial data suggests meaningful weight loss can begin even at this relatively low dose — TRIUMPH-1 found 19.0% weight loss at 80 weeks on 4mg alone.
• Weeks 13–24 (6mg–8mg): Many researchers find their effective range within this window and choose to hold rather than continue escalating.
• Week 24 onward: For those continuing to titrate toward higher doses, trial data suggests results can continue accumulating out to 80 weeks and beyond, though — as with the other compounds in this category — plateaus are a normal part of that pattern, not a sign of failure.

Individual timelines vary substantially, and this pattern is drawn from trial data in populations different from any individual researcher — this is a general pattern, not a guarantee.

Combining With Other Compounds

The same lean-mass rationale that applies to semaglutide and tirzepatide applies here, and arguably matters most for retatrutide given its documented effect size — GH-axis compounds, particularly CJC-1295 paired with Ipamorelin, come up frequently in community discussion specifically to help preserve lean mass during what can be a very large caloric deficit. Worth researching in its own depth before combining anything, especially given how little independent safety data exists for retatrutide on its own, let alone in combination.

Common Questions

Is retatrutide approved for any use? No — as of this writing, it isn’t approved anywhere in the world. Eli Lilly has indicated an NDA filing is expected before the end of 2026, with realistic market availability sometime in 2027–2028.

How does it really compare to tirzepatide? The trial numbers are genuinely larger — 28.3% at 80 weeks for retatrutide’s 12mg dose versus roughly 20.9% for tirzepatide’s 15mg dose — but this hasn’t been tested in a direct head-to-head trial the way tirzepatide was tested against semaglutide in SURMOUNT-5. The comparison is currently across separate trials, not a controlled head-to-head.

Is it safe, given it’s not approved yet? The Phase 3 data so far has been consistently positive with a side effect profile similar to the rest of this drug class. What’s genuinely missing is long-term, real-world post-marketing experience — which simply doesn’t exist yet for any unapproved compound, by definition.

Why does community discussion mention 1–3mg so much when the trials go up to 12mg? Because that’s where trial data itself shows most of the meaningful effect occurring, and where community-reported experience consistently lands — the higher doses in trials exist to establish a ceiling, not to represent a typical or necessary dose.

Before You Start

A quick checklist to run through before your first dose:

• Confirmed none of the likely contraindications apply to you, understanding there’s no official approved label yet to check against
• Reviewed current medications for potential interactions, especially insulin or sulfonylureas
• Have your titration schedule and vial size/concentration planned together
• Have a tracking method ready for dose, injection date, and side effects
• Understand this compound has no long-term real-world safety data, and are comfortable with that tradeoff
• Sourced with extra scrutiny, given there’s no regulated supply chain at all for this compound
• Thought through what happens at the end of your protocol, not just the start

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Phase	Dose	Frequency
Titration start	1mg	Once weekly
Titration	2mg	Once weekly
Titration	4mg	Once weekly
Active	6mg	Once weekly
Active	8mg	Once weekly
Advanced	10–12mg	Once weekly
Typical effective range (community-reported)	1mg–3mg	Once weekly

Where to Go From Here

• Semaglutide vs. Tirzepatide vs. Retatrutide — full category comparison
• How to Manage GLP-1 Side Effects — nausea, fatigue, and GI strategies in depth
• Preserving Lean Mass During a GLP-1 Protocol — protein, training, and stacking
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.